톨-유사 수용체-5 자극 활성이 강화된 PAS-플라젤린융합 단백질
    11.
    发明公开
    톨-유사 수용체-5 자극 활성이 강화된 PAS-플라젤린융합 단백질 有权
    PAS-FLAGELLIN融合蛋白与改进的TOLL-LIKE受体5刺激活性

    公开(公告)号:KR1020080074556A

    公开(公告)日:2008-08-13

    申请号:KR1020070013845

    申请日:2007-02-09

    Abstract: A PAS-flagellin recombinant fusion protein is provided to improve toll-like receptor-5(TLR5) stimulating activity by inhibiting polymerization of flagellin molecules, thereby enhancing the unique flagellin activity. A plasmid for producing a PAS-flagellin recombinant fusion protein includes a PAS gene of SEQ ID : NO. 1 and a flagellin gene of SEQ ID : NO. 3 and has a linkage map depicted in Fig. 1. A PAS-flagellin recombinant fusion protein is produced by the plasmid and is described as SEQ ID : NO. 6. A vaccine adjuvant comprises the PAS-flagellin recombinant fusion protein as an effective ingredient.

    Abstract translation: 提供了一种PAS-鞭毛蛋白重组融合蛋白,通过抑制鞭毛蛋白分子的聚合来改善toll样受体-5(TLR5)刺激活性,从而增强了独特的鞭毛蛋白活性。 用于产生PAS-鞭毛蛋白重组融合蛋白的质粒包括SEQ ID NO:1的PAS基因。 1和SEQ ID NO:1的鞭毛蛋白基因。 并具有图3所示的连杆图。 PAS-鞭毛蛋白重组融合蛋白由质粒产生并描述为SEQ ID NO: 疫苗佐剂包含PAS-鞭毛蛋白重组融合蛋白作为有效成分。

    플라젤린을 포함하는 천식 및 알레르기 질환 면역치료제
    13.
    发明授权
    플라젤린을 포함하는 천식 및 알레르기 질환 면역치료제 有权
    包含可用于哮喘和过敏性疾病的免疫治疗的鞭毛蛋白的佐剂组合物

    公开(公告)号:KR100804507B1

    公开(公告)日:2008-02-20

    申请号:KR1020050041061

    申请日:2005-05-17

    Abstract: 본 발명은 플라젤린을 포함하는 천식 및 알레르기 질환 면역 치료제에 관한 것으로서, 보다 상세하게는 플라젤린을 유효 성분으로 함유시킴으로써 천식, 아토피성 피부염, 알레르기성 비염 등과 같은 알레르기 질환에 대한 항원 특이적 면역 반응을 조절하는 면역치료제에 관한 것이다.
    항원 특이적 천식 치료제, 플라젤린, 패혈증 비브리오균, 면역 치료제

    플라젤린을 포함하는 천식 및 알레르기 질환 면역치료제
    14.
    发明公开
    플라젤린을 포함하는 천식 및 알레르기 질환 면역치료제 有权
    包含有助于免疫性哮喘和过敏性疾病的FLAGELLINS的补充剂组合物

    公开(公告)号:KR1020060118737A

    公开(公告)日:2006-11-24

    申请号:KR1020050041061

    申请日:2005-05-17

    Abstract: An immuno-therapy adjuvant composition comprising flagellins is provided to be able to control antigen-specific immuno-reaction against allergic diseases such as asthma, atopic dermatitis and allergic rhinitis. The adjuvant composition for treating asthma and allergic diseases comprises flagellins of septic vibrio as an effective ingredient. In the composition, the flagellins are encoded by a gene selected from the group consisting of flaA, flaB, flaF, flaC, flaD, and flaE.

    Abstract translation: 提供包含鞭毛蛋白的免疫治疗佐剂组合物以能够控制抗过敏性疾病如哮喘,特应性皮炎和过敏性鼻炎的抗原特异性免疫反应。 用于治疗哮喘和过敏性疾病的佐剂组合物包括脓毒弧菌的鞭毛蛋白作为有效成分。 在组合物中,鞭毛蛋白由选自flaA,flaB,flaF,flaC,flaD和flaE的基因编码。

    비브리오 패혈증균의 독력인자 발현을 조절하는범독력인자 발현 조절인자인 cAMP 수용체 단백질 및아데닐레이트 사이클라아제
    16.
    发明公开
    비브리오 패혈증균의 독력인자 발현을 조절하는범독력인자 발현 조절인자인 cAMP 수용체 단백질 및아데닐레이트 사이클라아제 失效
    cAMP受体蛋白和VIBRIO VULNIFICUS的ADENYLATE CYCLASE作为全球血液调节因子调节VIRULENCE表达

    公开(公告)号:KR1020040092147A

    公开(公告)日:2004-11-03

    申请号:KR1020030026365

    申请日:2003-04-25

    CPC classification number: A61K39/107 A61K2039/52

    Abstract: PURPOSE: cAMP receptor protein and adenylate cyclase of Vibrio vulnificus as global virulence regulators to regulate virulence expression are provided. Therefore, the host cell is protected from infection of Vibrio vulnificus by deleting genes encoding the cAMP receptor protein and adenylate cyclase. CONSTITUTION: The crp gene encoding the cAMP receptor protein(CRP) of Vibrio vulnificus to regulate virulence expression has the nucleotide sequence of SEQ ID NO:1, wherein the cAMP receptor protein(CRP) of Vibrio vulnificus has the amino acid sequence of SEQ ID NO:2. The cya gene encoding the adenylate cyclase of Vibrio vulnificus which binds to the CRP to activate the CRP has the nucleotide sequence of SEQ ID NO:3, wherein the adenylate cyclase of Vibrio vulnificus has the amino acid sequence of SEQ ID NO:4.

    Abstract translation: 目的:提供创伤弧菌的cAMP受体蛋白和腺苷酸环化酶,作为调控毒力表达的全局毒力调节因子。 因此,通过删除编码cAMP受体蛋白质和腺苷酸环化酶的基因,保护宿主细胞免受创伤弧菌的感染。 构成:编码创伤弧菌的cAMP受体蛋白(CRP)的crp基因用于调节毒力表达具有SEQ ID NO:1的核苷酸序列,其中创伤弧菌的cAMP受体蛋白(CRP)具有SEQ ID NO:1的氨基酸序列 NO:2。 结合CRP以激活CRP的编码创伤弧菌的腺苷酸环化酶的cya基因具有SEQ ID NO:3的核苷酸序列,其中创伤弧菌的腺苷酸环化酶具有SEQ ID NO:4的氨基酸序列。

    ppGpp―결손 변이 살모넬라 갈리나룸 균을 포함하는 가금 티프스 약제학적 백신 조성물
    17.
    发明公开
    ppGpp―결손 변이 살모넬라 갈리나룸 균을 포함하는 가금 티프스 약제학적 백신 조성물 无效
    用于包含PPGPP缺陷的沙门氏菌菌落变异的L L ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS

    公开(公告)号:KR1020110126227A

    公开(公告)日:2011-11-23

    申请号:KR1020100045781

    申请日:2010-05-17

    Abstract: PURPOSE: A pharmaceutical vaccine composition for fowl typhoid and a feed composition for preventing fowl typhoid are provided to induce prepare antibiotics and to effectively prevent or treat fowl typhoid. CONSTITUTION: A pharmaceutical vaccine composition for fowl typhoid contains ppGpp(guanosine 5'-diphosphate 3'-diphosphate)-deletion mutant Salmonella Gallinarum. The strain contains inactivated relA gene, spoT gene encoding ppGpp synthase, or activated relA gene and spoT gene. A feed composition for preventing fowl typhoid contains the ppGpp-deletion mutant Salmonella Gallinarum. The composition is manufactured in the form of a tablet, pill, powder, granule, capsule, suspension, emulsion, or syrup.

    Abstract translation: 目的:提供用于禽类伤寒和用于预防家禽伤寒的饲料组合物的药物疫苗组合物,以诱导制备抗生素并有效预防或治疗家禽伤寒。 构成:用于禽类伤寒的药物疫苗组合物含有ppGpp(鸟苷5'-二磷酸3'-二磷酸)缺失突变体沙门氏菌(Salmonella Gallinarum)。 该菌株含有灭活的relA基因,编码ppGpp合酶的spoT基因,或活化的relA基因和spoT基因。 用于防止禽类伤寒的饲料组合物含有ppGpp缺失突变体沙门氏菌(Salmonella Gallinarum)。 组合物以片剂,丸剂,粉剂,颗粒剂,胶囊剂,悬浮液,乳剂或糖浆剂的形式制备。

Patent Agency Ranking